1eh4 › Citations

Crystal structure of a conformation-selective casein kinase-1 inhibitor.

Mashhoon N, DeMaggio AJ, Tereshko V, Bergmeier SC, Egli M, Hoekstra MF, Kuret J
J Biol Chem 275 20052-60 (2000)
Cited: 92 times
EuropePMC logo PMID: 10749871

Abstract

Members of the casein kinase-1 family of protein kinases play an essential role in cell regulation and disease pathogenesis. Unlike most protein kinases, they appear to function as constitutively active enzymes. As a result, selective pharmacological inhibitors can play an important role in dissection of casein kinase-1-dependent processes. To address this need, new small molecule inhibitors of casein kinase-1 acting through ATP-competitive and ATP-noncompetitive mechanisms were isolated on the basis of in vitro screening. Here we report the crystal structure of 3-[(2,4,6-trimethoxyphenyl) methylidenyl]-indolin-2-one (IC261), an ATP-competitive inhibitor with differential activity among casein kinase-1 isoforms, in complex with the catalytic domain of fission yeast casein kinase-1 refined to a crystallographic R-factor of 22.4% at 2.8 A resolution. The structure reveals that IC261 stabilizes casein kinase-1 in a conformation midway between nucleotide substrate liganded and nonliganded conformations. We propose that adoption of this conformation by casein kinase-1 family members stabilizes a delocalized network of side chain interactions and results in a decreased dissociation rate of inhibitor.

Articles - 1eh4 mentioned but not cited (4)

  1. TTBK2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development. Bouskila M, Esoof N, Gay L, Fang EH, Deak M, Begley MJ, Cantley LC, Prescott A, Storey KG, Alessi DR. Biochem J 437 157-167 (2011)
  2. From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity. Durieu E, Prina E, Leclercq O, Oumata N, Gaboriaud-Kolar N, Vougogiannopoulou K, Aulner N, Defontaine A, No JH, Ruchaud S, Skaltsounis AL, Galons H, Späth GF, Meijer L, Rachidi N. Antimicrob Agents Chemother 60 2822-2833 (2016)
  3. Intensity statistics in the presence of translational noncrystallographic symmetry. Read RJ, Adams PD, McCoy AJ. Acta Crystallogr D Biol Crystallogr 69 176-183 (2013)
  4. A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin. Xian J, Bu F, Wang Y, Long F, Zhang Z, Wu C, Tao Y, Wang T, Wang G. Molecules 26 946 (2021)


Reviews citing this publication (21)

  1. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Knippschild U, Gocht A, Wolff S, Huber N, Löhler J, Stöter M. Cell Signal 17 675-689 (2005)
  2. Tau protein kinases: involvement in Alzheimer's disease. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F. Ageing Res Rev 12 289-309 (2013)
  3. The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis. Knippschild U, Krüger M, Richter J, Xu P, García-Reyes B, Peifer C, Halekotte J, Bakulev V, Bischof J. Front Oncol 4 96 (2014)
  4. Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Perez DI, Gil C, Martinez A. Med Res Rev 31 924-954 (2011)
  5. Casein kinase: the triple meaning of a misnomer. Venerando A, Ruzzene M, Pinna LA. Biochem J 460 141-156 (2014)
  6. Non-kinase targets of protein kinase inhibitors. Munoz L. Nat Rev Drug Discov 16 424-440 (2017)
  7. Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. Caricasole A, Bakker A, Copani A, Nicoletti F, Nicoletti F, Gaviraghi G, Terstappen GC. Biosci Rep 25 309-327 (2005)
  8. Recent developments of protein kinase inhibitors as potential AD therapeutics. Tell V, Hilgeroth A. Front Cell Neurosci 7 189 (2013)
  9. Casein kinases as potential therapeutic targets. Cozza G, Pinna LA. Expert Opin Ther Targets 20 319-340 (2016)
  10. Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D). Xu P, Ianes C, Gärtner F, Liu C, Burster T, Bakulev V, Rachidi N, Knippschild U, Bischof J. Gene 715 144005 (2019)
  11. Clocking cancer: the circadian clock as a target in cancer therapy. Battaglin F, Chan P, Pan Y, Soni S, Qu M, Spiller ER, Castanon S, Roussos Torres ET, Mumenthaler SM, Kay SA, Lenz HJ. Oncogene 40 3187-3200 (2021)
  12. Targeting Casein Kinase 1 (CK1) in Hematological Cancers. Janovská P, Normant E, Miskin H, Bryja V. Int J Mol Sci 21 E9026 (2020)
  13. Molecular basis for the regulation of the circadian clock kinases CK1δ and CK1ε. Yang Y, Xu T, Zhang Y, Qin X. Cell Signal 31 58-65 (2017)
  14. CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes. Roth A, Gihring A, Bischof J, Pan L, Oswald F, Knippschild U. Cancers (Basel) 14 1345 (2022)
  15. Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors. Giraud F, Pereira E, Anizon F, Moreau P. Molecules 26 2696 (2021)
  16. A competitive cell-permeable peptide impairs Nme-1 (NDPK-A) and Prune-1 interaction: therapeutic applications in cancer. Ferrucci V, Pennino FP, Siciliano R, Asadzadeh F, Zollo M. Lab Invest 98 571-581 (2018)
  17. Stress-activated kinases as therapeutic targets in pancreatic cancer. Traub B, Roth A, Kornmann M, Knippschild U, Bischof J. World J Gastroenterol 27 4963-4984 (2021)
  18. CK2 and protein kinases of the CK1 superfamily as targets for neurodegenerative disorders. Baier A, Szyszka R. Front Mol Biosci 9 916063 (2022)
  19. The protein kinase CK1: Inhibition, activation, and possible allosteric modulation. Sunkari YK, Meijer L, Flajolet M. Front Mol Biosci 9 916232 (2022)
  20. TCR Pathway Mutations in Mature T Cell Lymphomas. Zhang Y, Cheng K, Choi J. J Immunol 211 1450-1458 (2023)
  21. Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives. Long NH, Lee SJ. Front Oncol 13 1244775 (2023)

Articles citing this publication (67)

  1. The Hippo pathway regulates Wnt/beta-catenin signaling. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, Wrana JL, Attisano L. Dev Cell 18 579-591 (2010)
  2. Control of mammalian circadian rhythm by CKIepsilon-regulated proteasome-mediated PER2 degradation. Eide EJ, Woolf MF, Kang H, Woolf P, Hurst W, Camacho F, Vielhaber EL, Giovanni A, Virshup DM. Mol Cell Biol 25 2795-2807 (2005)
  3. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. Rena G, Bain J, Elliott M, Cohen P. EMBO Rep 5 60-65 (2004)
  4. Functional genomics identifies therapeutic targets for MYC-driven cancer. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, Cleary MA, Park JR, Grandori C. Proc Natl Acad Sci U S A 109 9545-9550 (2012)
  5. Casein kinase I phosphorylates and destabilizes the beta-catenin degradation complex. Gao ZH, Seeling JM, Hill V, Yochum A, Virshup DM. Proc Natl Acad Sci U S A 99 1182-1187 (2002)
  6. Sequential interactions with Sec23 control the direction of vesicle traffic. Lord C, Bhandari D, Menon S, Ghassemian M, Nycz D, Hay J, Ghosh P, Ferro-Novick S. Nature 473 181-186 (2011)
  7. Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I. Flajolet M, He G, Heiman M, Lin A, Nairn AC, Greengard P. Proc Natl Acad Sci U S A 104 4159-4164 (2007)
  8. Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors. Liu F, Ma XH, Ule J, Bibb JA, Nishi A, DeMaggio AJ, Yan Z, Nairn AC, Greengard P. Proc Natl Acad Sci U S A 98 11062-11068 (2001)
  9. IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Behrend L, Milne DM, Stöter M, Deppert W, Campbell LE, Meek DW, Knippschild U. Oncogene 19 5303-5313 (2000)
  10. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP. Neurobiol Aging 33 431.e27-38 (2012)
  11. Centrosomal anchoring of the protein kinase CK1delta mediated by attachment to the large, coiled-coil scaffolding protein CG-NAP/AKAP450. Sillibourne JE, Milne DM, Takahashi M, Ono Y, Meek DW. J Mol Biol 322 785-797 (2002)
  12. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation. Cheong JK, Nguyen TH, Wang H, Tan P, Voorhoeve PM, Lee SH, Virshup DM. Oncogene 30 2558-2569 (2011)
  13. Casein kinase 1 is a novel negative regulator of E-cadherin-based cell-cell contacts. Dupre-Crochet S, Figueroa A, Hogan C, Ferber EC, Bialucha CU, Adams J, Richardson EC, Fujita Y. Mol Cell Biol 27 3804-3816 (2007)
  14. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, Kraemer BC, Miguel L, Lecourtois M, Gil C, Martinez A, Perez DI. J Med Chem 57 2755-2772 (2014)
  15. CK1epsilon is required for breast cancers dependent on beta-catenin activity. Kim SY, Dunn IF, Firestein R, Gupta P, Wardwell L, Repich K, Schinzel AC, Wittner B, Silver SJ, Root DE, Boehm JS, Ramaswamy S, Lander ES, Hahn WC. PLoS One 5 e8979 (2010)
  16. Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration. Foldynová-Trantírková S, Sekyrová P, Tmejová K, Brumovská E, Bernatík O, Blankenfeldt W, Krejcí P, Kozubík A, Dolezal T, Trantírek L, Bryja V. Breast Cancer Res 12 R30 (2010)
  17. Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Yang WS, Stockwell BR. Genome Biol 9 R92 (2008)
  18. Role of CK1 in GSK3beta-mediated phosphorylation and degradation of snail. Xu Y, Lee SH, Kim HS, Kim NH, Piao S, Park SH, Jung YS, Yook JI, Park BJ, Ha NC. Oncogene 29 3124-3133 (2010)
  19. PML enhances the regulation of p53 by CK1 in response to DNA damage. Alsheich-Bartok O, Haupt S, Alkalay-Snir I, Saito S, Appella E, Haupt Y. Oncogene 27 3653-3661 (2008)
  20. Physiological role for casein kinase 1 in glutamatergic synaptic transmission. Chergui K, Svenningsson P, Greengard P. J Neurosci 25 6601-6609 (2005)
  21. Ypt1/Rab1 regulates Hrr25/CK1δ kinase activity in ER-Golgi traffic and macroautophagy. Wang J, Davis S, Menon S, Zhang J, Ding J, Cervantes S, Miller E, Jiang Y, Ferro-Novick S. J Cell Biol 210 273-285 (2015)
  22. Inhibition of casein kinase I delta alters mitotic spindle formation and induces apoptosis in trophoblast cells. Stöter M, Bamberger AM, Aslan B, Kurth M, Speidel D, Löning T, Frank HG, Kaufmann P, Löhler J, Henne-Bruns D, Deppert W, Knippschild U. Oncogene 24 7964-7975 (2005)
  23. Phosphorylation of CK1delta: identification of Ser370 as the major phosphorylation site targeted by PKA in vitro and in vivo. Giamas G, Hirner H, Shoshiashvili L, Grothey A, Gessert S, Kühl M, Henne-Bruns D, Vorgias CE, Knippschild U. Biochem J 406 389-398 (2007)
  24. WWC3 regulates the Wnt and Hippo pathways via Dishevelled proteins and large tumour suppressor 1, to suppress lung cancer invasion and metastasis. Han Q, Lin X, Zhang X, Jiang G, Zhang Y, Miao Y, Rong X, Zheng X, Han Y, Han X, Wu J, Kremerskothen J, Wang E. J Pathol 242 435-447 (2017)
  25. Phosphorylation of nm23-H1 by CKI induces its complex formation with h-prune and promotes cell motility. Garzia L, D'Angelo A, Amoresano A, Knauer SK, Cirulli C, Campanella C, Stauber RH, Steegborn C, Iolascon A, Zollo M. Oncogene 27 1853-1864 (2008)
  26. Combined kinase inhibition modulates parkin inactivation. Rubio de la Torre E, Luzón-Toro B, Forte-Lago I, Minguez-Castellanos A, Ferrer I, Hilfiker S. Hum Mol Genet 18 809-823 (2009)
  27. PTEN regulates cilia through Dishevelled. Shnitsar I, Bashkurov M, Masson GR, Ogunjimi AA, Mosessian S, Cabeza EA, Hirsch CL, Trcka D, Gish G, Jiao J, Wu H, Winklbauer R, Williams RL, Pelletier L, Wrana JL, Barrios-Rodiles M. Nat Commun 6 8388 (2015)
  28. Casein kinase 1 delta functions at the centrosome to mediate Wnt-3a-dependent neurite outgrowth. Greer YE, Rubin JS. J Cell Biol 192 993-1004 (2011)
  29. Purification of CK1 by affinity chromatography on immobilised axin. Reinhardt J, Ferandin Y, Meijer L. Protein Expr Purif 54 101-109 (2007)
  30. Casein kinase Iepsilon plays a functional role in the transforming growth factor-beta signaling pathway. Waddell DS, Liberati NT, Guo X, Frederick JP, Wang XF. J Biol Chem 279 29236-29246 (2004)
  31. In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. Oblak M, Grdadolnik SG, Kotnik M, Jerala R, Filipic M, Solmajer T. Bioorg Med Chem Lett 15 5207-5210 (2005)
  32. Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2. von Blume J, Knippschild U, Dequiedt F, Giamas G, Beck A, Auer A, Van Lint J, Adler G, Seufferlein T. EMBO J 26 4619-4633 (2007)
  33. Site-specific casein kinase 1epsilon-dependent phosphorylation of Dishevelled modulates beta-catenin signaling. Klimowski LK, Garcia BA, Shabanowitz J, Hunt DF, Virshup DM. FEBS J 273 4594-4602 (2006)
  34. 2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1δ/ε. Bischof J, Leban J, Zaja M, Grothey A, Radunsky B, Othersen O, Strobl S, Vitt D, Knippschild U. Amino Acids 43 1577-1591 (2012)
  35. CK1 activates minus-end-directed transport of membrane organelles along microtubules. Ikeda K, Zhapparova O, Brodsky I, Semenova I, Tirnauer JS, Zaliapin I, Rodionov V. Mol Biol Cell 22 1321-1329 (2011)
  36. Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection. Rachidi N, Taly JF, Durieu E, Leclercq O, Aulner N, Prina E, Pescher P, Notredame C, Meijer L, Späth GF. Antimicrob Agents Chemother 58 1501-1515 (2014)
  37. Impaired CK1 delta activity attenuates SV40-induced cellular transformation in vitro and mouse mammary carcinogenesis in vivo. Hirner H, Günes C, Bischof J, Wolff S, Grothey A, Kühl M, Oswald F, Wegwitz F, Bösl MR, Trauzold A, Henne-Bruns D, Peifer C, Leithäuser F, Deppert W, Knippschild U. PLoS One 7 e29709 (2012)
  38. Casein kinase I regulates membrane binding by ARF GAP1. Yu S, Roth MG. Mol Biol Cell 13 2559-2570 (2002)
  39. Inhibition of endocytosis blocks Wnt signalling to beta-catenin by promoting dishevelled degradation. Bryja V, Cajánek L, Grahn A, Schulte G. Acta Physiol (Oxf) 190 55-61 (2007)
  40. Structural dynamics of Casein Kinase I (CKI) from malarial parasite Plasmodium falciparum (Isolate 3D7): Insights from theoretical modelling and molecular simulations. Dehury B, Behera SK, Mahapatra N. J Mol Graph Model 71 154-166 (2017)
  41. Characterization of two T. gondii CK1 isoforms. Donald RG, Zhong T, Meijer L, Liberator PA. Mol Biochem Parasitol 141 15-27 (2005)
  42. Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients. Richter J, Ullah K, Xu P, Alscher V, Blatz A, Peifer C, Halekotte J, Leban J, Vitt D, Holzmann K, Bakulev V, Pinna LA, Henne-Bruns D, Hillenbrand A, Kornmann M, Leithäuser F, Bischof J, Knippschild U. Int J Cancer 136 2799-2810 (2015)
  43. The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5. Chen PC, Lao CL, Chen JC. J Neurochem 110 1180-1190 (2009)
  44. CKI isoforms α and ε regulate Star-PAP target messages by controlling Star-PAP poly(A) polymerase activity and phosphoinositide stimulation. Laishram RS, Barlow CA, Anderson RA. Nucleic Acids Res 39 7961-7973 (2011)
  45. Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening. Cozza G, Gianoncelli A, Montopoli M, Caparrotta L, Venerando A, Meggio F, Pinna LA, Zagotto G, Moro S. Bioorg Med Chem Lett 18 5672-5675 (2008)
  46. The kinase CK1ɛ controls the antiviral immune response by phosphorylating the signaling adaptor TRAF3. Zhou Y, He C, Yan D, Liu F, Liu H, Chen J, Cao T, Zuo M, Wang P, Ge Y, Lu H, Tong Q, Qin C, Deng Y, Ge B. Nat Immunol 17 397-405 (2016)
  47. Astrocytes deliver CK1 to neurons via extracellular vesicles in response to inflammation promoting the translation and amyloidogenic processing of APP. Li Z, Moniruzzaman M, Dastgheyb RM, Yoo SW, Wang M, Hao H, Liu J, Casaccia P, Nogueras-Ortiz C, Kapogiannis D, Slusher BS, Haughey NJ. J Extracell Vesicles 10 e12035 (2020)
  48. Structured DNA promotes phosphorylation of p53 by DNA-dependent protein kinase at serine 9 and threonine 18. Soubeyrand S, Schild-Poulter C, Haché RJ. Eur J Biochem 271 3776-3784 (2004)
  49. Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization. Tillement V, Lajoie-Mazenc I, Casanova A, Froment C, Penary M, Tovar D, Marquez R, Monsarrat B, Favre G, Pradines A. Exp Cell Res 314 2811-2821 (2008)
  50. Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK. Halekotte J, Witt L, Ianes C, Krüger M, Bührmann M, Rauh D, Pichlo C, Brunstein E, Luxenburger A, Baumann U, Knippschild U, Bischof J, Peifer C. Molecules 22 E522 (2017)
  51. The multiple roles of computational chemistry in fragment-based drug design. Law R, Barker O, Barker JJ, Hesterkamp T, Godemann R, Andersen O, Fryatt T, Courtney S, Hallett D, Whittaker M. J Comput Aided Mol Des 23 459-473 (2009)
  52. Circadian metabolic regulation through crosstalk between casein kinase 1δ and transcriptional coactivator PGC-1α. Li S, Chen XW, Yu L, Saltiel AR, Lin JD. Mol Endocrinol 25 2084-2093 (2011)
  53. Alleviation of behavioral hypersensitivity in mouse models of inflammatory pain with two structurally different casein kinase 1 (CK1) inhibitors. Kurihara T, Sakurai E, Toyomoto M, Kii I, Kawamoto D, Asada T, Tanabe T, Yoshimura M, Hagiwara M, Miyata A. Mol Pain 10 17 (2014)
  54. CK1δ kinase activity is modulated by protein kinase C α (PKCα)-mediated site-specific phosphorylation. Meng Z, Bischof J, Ianes C, Henne-Bruns D, Xu P, Knippschild U. Amino Acids 48 1185-1197 (2016)
  55. Microtubules depolymerization caused by the CK1 inhibitor IC261 may be not mediated by CK1 blockage. Stöter M, Krüger M, Banting G, Henne-Bruns D, Knippschild U. PLoS One 9 e100090 (2014)
  56. Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates. Löffler T, Flunkert S, Taub N, Schofield EL, Ward MA, Windisch M, Hutter-Paier B. J Mol Neurosci 47 192-203 (2012)
  57. Neurite outgrowth of mature retinal ganglion cells and PC12 cells requires activity of CK1δ and CK1ε. Bischof J, Müller A, Fänder M, Knippschild U, Fischer D. PLoS One 6 e20857 (2011)
  58. State-dependent block of voltage-gated sodium channels by the casein-kinase 1 inhibitor IC261. Föhr KJ, Knippschild U, Herkommer A, Fauler M, Peifer C, Georgieff M, Adolph O. Invest New Drugs 35 277-289 (2017)
  59. CK1ε and p120-catenin control Ror2 function in noncanonical Wnt signaling. Curto J, Del Valle-Pérez B, Villarroel A, Fuertes G, Vinyoles M, Peña R, García de Herreros A, Duñach M. Mol Oncol 12 611-629 (2018)
  60. Characterization of (-)-matairesinol as a potent inhibitor of casein kinase I in vitro. Yokoyama T, Okano M, Noshita T, Funayama S, Ohtsuki K. Biol Pharm Bull 26 371-374 (2003)
  61. Structure of the unliganded cAMP-dependent protein kinase catalytic subunit from Saccharomyces cerevisiae. Mashhoon N, Carmel G, Pflugrath JW, Kuret J. Arch Biochem Biophys 387 11-19 (2001)
  62. CK1δ in lymphoma: gene expression and mutation analyses and validation of CK1δ kinase activity for therapeutic application. Winkler BS, Oltmer F, Richter J, Bischof J, Xu P, Burster T, Leithäuser F, Knippschild U. Front Cell Dev Biol 3 9 (2015)
  63. Gene expression levels of Casein kinase 1 (CK1) isoforms are correlated to adiponectin levels in adipose tissue of morbid obese patients and site-specific phosphorylation mediated by CK1 influences multimerization of adiponectin. Xu P, Fischer-Posovszky P, Bischof J, Radermacher P, Wabitsch M, Henne-Bruns D, Wolf AM, Hillenbrand A, Knippschild U. Mol Cell Endocrinol 406 87-101 (2015)
  64. Structural and functional studies of casein kinase I-like protein from rice. Park YI, Do KH, Kim IS, Park HH. Plant Cell Physiol 53 304-311 (2012)
  65. Assessing the Inhibitory Potential of Kinase Inhibitors In Vitro: Major Pitfalls and Suggestions for Improving Comparability of Data Using CK1 Inhibitors as an Example. Roth A, Gihring A, Göser F, Peifer C, Knippschild U, Bischof J. Molecules 26 4898 (2021)
  66. Common Markers and Small Molecule Inhibitors in Golgi Studies. Bui S, Stark D, Li J, Zhang J, Wang Y. Methods Mol Biol 2557 453-493 (2023)
  67. Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening. Córdova-Bahena L, Sánchez-Álvarez AA, Ruiz-Moreno AJ, Velasco-Velázquez MA. Pharmaceuticals (Basel) 15 8 (2021)


Related citations provided by authors (2)

  1. Crystal Structure of Casein Kinase-1, a Phosphate-directed Protein Kinase. Xu RM, Carmel G, Sweet RM, Kuret J, Cheng X EMBO J. 14 1015-1023 (1995)
  2. Structural Basis for Selectivity of the Isoquinoline Sulfonamide Family of Protein Kinase Inhibitors. Xu RM, Carmel G, Kuret J, Cheng X Proc. Natl. Acad. Sci. U.S.A. 93 6308-6313 (1996)

Quick links